First Subject Enrolled in Phase 1 Study of MRX-5
- Written by PR Newswire Asia - Asian Spectator
SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as "MicuRx") announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial in Australia.
MRX-5 is a new type of benzodiazepine antibiotic used to treat infections...